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evaluated. Results. Compared to women without M. genitalium,w o m e nw i t hM. genitalium were more likely to report nulliparity
(41.7%versus17.4%, P = .04),historyof pelvicinﬂammatorydisease(27.3% versus8.8%, P = .08), prior C.trachomatisinfection
(63.6% versus 36.9%, P = .11,) and problems getting pregnant (18.2% versus 4.4%, P = .10). M. genitalium was not associated
with SAB (AOR 0.9, 95% CI 0.2–3.8). Conclusions. Pregnant women who test positive for M. genitalium do not have an increased
risk of SAB but report a history of reproductive morbidities.
1.Introduction
Spontaneous abortion (SAB), the loss of a conceptus prior
to 20 weeks, is the most common adverse outcome of preg-
nancy,occurringinanestimated15%ofclinicallyrecognized
pregnancies [1] and up to 50% of all pregnancies [2]. Many
SABs occurring in the ﬁrst trimester are due to phenotypic
and/or chromosomal abnormalities, while environmental
factors may have a greater impact on SAB occurring in later
pregnancy [2]. Evidence suggests that sexually transmitted
bacterial and viral infections, such as Treponema pallidum,
bacterial vaginosis (BV), and Chlamydia trachomatis,m a y
play a role in SAB [3–13].
Mycoplasma genitalium, a sexually transmitted bac-
terium, has been linked to various adverse gynecologic and
reproductive events. It has been associated with cervicitis
[14–17] and has been implicated as an etiological agent of
pelvic inﬂammatory disease (PID) independent of C. tra-
chomatis and Neisseria gonorrhoeae [17–20]. Furthermore,
it has been detected in cervical and salpingeal samples from
women with laparoscopically conﬁrmed salpingitis [21]a n d
in cervical and endometrial specimens from women with
histologically conﬁrmed endometritis [18]. A serologic rela-
tionship between M. genitalium and tubal factor infertility
has also been identiﬁed [22, 23].
Because M. genitalium has been associated with these
morbidities, it is plausible that M. genitalium can infect the
upper genital tract during pregnancy, resulting in adverse
pregnancy outcomes. However, data on M. genitalium in
pregnancy are sparse. Whereas two studies among low-risk
w o m e nh a v er e p o rt e dn or e l a t i o n s h i pb e t w e e nM. genitalium
and SAB [11, 24], one study has reported an association
between M. genitalium and preterm birth [25]. Thus, it is
possible that M. genitalium may have an adverse eﬀect on
pregnancy outcomes. We conducted a nested case-control
studytoexaminetheroleofM.genitaliuminearlypregnancy
and subsequent SAB. The associations between M. genital-
ium and microbiologic, demographic, current pregnancy,2 Infectious Diseases in Obstetrics and Gynecology
and reproductive health history characteristics among pre-
dominantly young, single, African-American women with
a history of sexually transmitted diseases (STDs) were also
investigated.
2.MaterialsandMethods
2.1. Study Population. For our analyses, we used data from
participants enrolled in the prospective Early Pregnancy
Study (EPS), designed to examine the inﬂuence of violence
on SAB risk [26]. During the period of January 1999 through
August 2001, adolescent girls and women aged 14 to 40
years who presented to the emergency department (ED) of
the hospital of the University of Pennsylvania with varying
complaints, including pregnancy-related complications such
as vaginal bleeding or abdominal pain, and nonpregnancy-
related complaints related to infection, accidents, and injury,
were screened for eligibility [26]. Nurse interviewers admin-
isteredabriefscreeningquestionnairetoidentifyallpregnant
womenlessthan22weeksgestationseenintheEDregardless
of the reason for the visit. Among the 1,249 pregnant
adolescent and adult women who were eligible for the
study, 96% agreed to participate (n = 1,199). The mean
gestational age at enrollment was 10.3 weeks. All participants
provided written informed consent, and the protocol and
consent forms were approved by the institutional review
board of the University of Pennsylvania.
2.2. Data Collection. At enrollment, nurse interviewers
administered an in-person questionnaire. The interview
contained information regarding medical and reproductive
history, sociodemographic factors, current level of social
support, living arrangements, and complications of the
pregnancy. Hair samples were collected to measure cocaine
use, and mid-stream urine samples were collected to assess
recent tobacco and alcohol use. Follow-up telephone inter-
views were conducted at 16 and 22 weeks of gestation to
determinepregnancystatus,andmedicalrecordreviewswere
conducted to conﬁrm pregnancy outcome. The 807 women
who remained pregnant through 22 weeks of gestation
were classiﬁed as controls (67%), and the 392 women who
experienced a noninduced pregnancy loss before 22 weeks
of gestation were classiﬁed as cases (33%). Of the cases, 212
experienced a SAB at enrollment and 180 experienced a SAB
during the follow-up period.
For our subsequent EPS subanalyses, women who were
experiencing a SAB at enrollment and women who did not
have a urine sample available for analysis were excluded.
Therefore, cases consisted of women who experienced a SAB
during the follow-up period and had a frozen urine sample
available for analysis (n = 95). We did a 2 : 1 match
for controls and randomly selected women who did not
experience a SAB and who had urine samples available for
testing (n = 190). Demographic and patient characteristics
between women with and without available samples did not
diﬀer signiﬁcantly.
2.3. Detection of M. genitalium and C. trachomatis. In 2009,
for this subsequent study, previously collected urine samples
stored at −70
◦ Cw e r et e s t e df o rM. genitalium and C.
trachomatis. M. genitalium PCR testing has been conducted
in other studies stored frozen specimens for up to eight
years [19, 27, 28]. Of the 285 samples sent for analysis,
216 samples (82 cases and 134 controls) were suﬃcient
for analysis. M. genitalium was detected by an inhibitor-
controlled TaqMan real-time PCR detecting a conserved part
oftheMgPaadhesiongene(MG192)[29].Allpositiveresults
were conﬁrmed by a second PCR with primers deduced
f r o mt h e1 6Sr R N Ag e n es e q u e n c eo fM. genitalium [29].
C. trachomatis DNA was detected by an inhibitor-controlled
TaqMan real-time PCR amplifying a sequence of the 16S
rRNAgeneofchlamydiaspecieswithaC.trachomatisspeciﬁc
TaqMan MGB probe [29]. Positive results were conﬁrmed
by a real-time PCR assay detecting a sequence of the cryptic
plasmid. The methods for PCR detection of M. genitalium
and C. trachomatis in urine have been previously validated
[30].
2.4. Microbiologic, Demographic, Current Pregnancy, and
Reproductive Health History Variables. The following is a
list of microbiologic, demographic, current pregnancy, and
reproductive health history variables that were compared
betweencasesandcontrols:M.genitaliumandC.trachomatis
infection detected by PCR, age, race, level of education,
maritalstatus,recipientofgovernmentassistance,gestational
age at enrollment, vaginal bleeding during pregnancy, parity,
history of STDs, history of PID, history of problems getting
pregnant, history of SAB, prior ectopic pregnancies, and
alcohol, cigarette, marijuana, and crack/cocaine use during
current pregnancy. All variables were self-reported during
the baseline interview. Cocaine use was additionally mea-
sured in hair specimens as previously described [26]. For
our analysis, we deﬁned cocaine use as cocaine detected
in hair specimen collected at baseline and/or self-reported
cocaine use. Gestational age was calculated on the basis of
self-reported date of the last menstrual period.
2.5. Statistical Methods. The microbiologic, demographic,
current pregnancy, and reproductive health history char-
acteristics among cases and controls were compared using
t, chi-square, and Fisher’s exact tests for continuous and
dichotomous variables as appropriate. Associations between
M.genitaliumPCRandmicrobiologic,demographic,current
pregnancy, and reproductive health history characteristics
were assessed with univariate logistic regression models.
Variables signiﬁcant in the univariate model (P-value ≤ .10)
were adjusted for C. trachomatis PCR in multivariate logistic
regression models. Nulliparity was further adjusted for age.
Fisher’s exact test was used to test for associations if there
were cell sizes of less than ﬁve in the contingency table.
Logistic regressions were used to investigate the rela-
tionship between M. genitalium urine PCR and SAB. We
had a power of 80% to detect a 3.4 increased risk of SAB
among women infected with M. genitalium. Analyses were
repeated controlling for age, history of SAB, smoking, and
gestational age. Regression models were repeated without
history of SAB, as including the history of SAB variable in
themodelmaybiastherelationshiptowardthenullifthereisInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Characteristics of women who experienced a SAB and women who maintained their pregnancies past 22 weeks gestation.
Characteristic
Women who experienced
aS A Bn = 82
Women who maintained
their pregnancies n = 134 P-value
n(%) n(%)
Infection
M. genitalium 3 (3.7) 9 (6.7) .54
C. trachomatis 3 (3.7) 12 (9.0) .17
M. genitalium and C. trachomatis 0 1 (0.7) 1.00
Demographic
Mean age (standard deviation) 24.8 (6.2) 23.9 (5.7) .33
Age
< 25 years 49 (59.7) 92 (68.7) .18
≥ 25 years 33 (40.2) 42 (31.3)
Race/ethnicity
African-American 72 (88.9) 120 (89.6) .89
Other 9 (11.1) 14 (10.4)
Marital Status
Unmarried 68 (82.9) 107 (79.8) .57
Married 14 (17.1) 27 (20.2)
Education
< High school 25 (30.5) 50 (37.3) .31
≥ High school 57 (69.5) 84 (62.7)
Receiving government assistance 31 (37.8) 58 (43.3) .43
Current pregnancy history
Mean gestational age(a) (standard
deviation) 8.7 (3.2) 9.5 (3.4) .08
Vaginal bleeding at enrollment 47 (57.3) 29 (21.8) <.0001
Vaginal bleeding since LMP 53 (65.4) 50 (37.3) <.0001
Alcohol use 30 (36.6) 44 (32.8) .57
Cigarette smoking 31 (38.3) 44 (32.8) .42
Marijuana use 17 (21.0) 25 (18.7) .68
Crack/cocaine use(b) 16 (25.4) 21 (22.8) .71
Reproductive health history
Nulliparous 14 (17.1) 27 (20.1) .58
Prior SAB 34 (40.2) 35 (26.1) .03
Prior ectopic pregnancy 5 (7.3) 6 (5.6) .75
History of STD(c) 48 (60.0) 82 (62.1) .76
History of PID 6 (7.4) 15 (11.3) .36
History of problems getting pregnant 5 (6.3) 6 (4.5) .75
Note: Missing observations: race, n = 1; vaginal bleeding, n = 1; cigarette smoking, n = 1; marijuana use, n = 1; crack/cocaine use, n = 61; prior incompetent
cervix, n = 2; prior ectopic pregnancy, n = 41; history of STD, n = 5; history of PID, n = 3; history of problems getting pregnant, n = 2.
(a)Gestational age at enrollment in weeks.
(b)Detected in hair sample collected at enrollment and/or self-report cocaine use.
(c)C. trachomatis, N. gonorrhoeae, syphilis, genital warts, Trichomonas vaginalis, and/or BV.
an association between M. genitalium and SAB. We repeated
our analyses categorizing SAB by gestational age (<11 weeks,
≥11 weeks), since gestational age of 11 weeks or greater at
timeofSABcanbeusedasamarkerforwhenpregnanciesare
more likely to be chromosomally normal and other factors
such as infectious agents are more likely to cause pregnancy
loss[2].Wealsorepeatedouranalysesexcludingwomenwho
experienced vaginal bleeding at enrollment, as these women
may have already been experiencing a SAB and this may have
compromised temporality.
3. Results
Among all study participants, 5.6% (12/216) tested positive
for M. genitalium and 6.9% (15/216) tested positive for C.
trachomatis at enrollment. Only one woman was coinfected4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Characteristics of study participants according to M. genitalium PCR result.




Yes 1 (8.3) 14 (6.8) .83
No 11 (91.7) 193 (93.2)
Demographic
Age
< 25 years 10 (83.3) 133 (64.2) .22
≥ 25 years 2 (16.7) 74 (35.8)
Race/ethnicity
African American 11 (91.7) 184 (89.3) .80
White/Other 1 (8.3) 22 (10.7)
Marital status
Unmarried 12 (100) 166 (80.2) —(a)
Married 0 41 (19.8)
Education
< High school 5 (41.7) 72 (34.8) .63
≥ High school 7 (58.3) 135 (65.2)
Current pregnancy history
Mean gestational age(b) (standard
deviation) 9.5 (2.9) 9.2 (3.3) .78(c)
Vaginal bleeding at enrollment
Yes 4 (33.3) 74 (35.9) 1.00
No 8 (66.7) 132 (64.1)
Vaginal bleeding since LMP
Yes 5 (41.7) 101 (49.0) .62
No 7 (58.3) 105 (51.0)
Alcohol use
Yes 5 (41.7) 70 (33.8) .87
No 7 (58.3) 137 (66.2)
Cigarette use
Yes 6 (50.0) 71/206 (34.5) .28
No 6 (50.0) 135/206 (65.5)
Marijuana use
Yes 4 (33.3) 40/206 (19.4) .27
No 8 (66.7) 166/206 (80.6)
Crack/cocaine use(d)
Yes 2 (20.0) 36 (24.3) .75
No 8 (80.0) 112 (75.1)
Reproductive health history
Nulliparous
Yes 5 (41.7) 36 (17.4) .04
No 7 (58.3) 171 (82.6)
History of SAB
Yes 1 (8.3) 68 (32.8) .07
No 11 (91.7) 139 (67.2)
Prior ectopic pregnancy
Yes 0 (0) 11 (6.4) —(a)
No 7 (100) 160 (93.6)Infectious Diseases in Obstetrics and Gynecology 5
Table 2: Continued.
Characteristic M. genitalium positive n = 12 M. genitalium negative n = 207 P-value
n(%) n(%)
History of STD(e)
Yes 11 (100) 121 (59.6) —(a)
No 0 (0) 82 (40.4)
History of C. trachomatis
Yes 7 (63.6) 76 (36.9) .11
No 4 (36.4) 130 (63.1)
History of PID
Yes 3 (27.3) 18 (8.8) .08
No 7 (72.7) 187 (91.2)
History of problems getting pregnant
Yes 2 (18.2) 9 (4.4) .10
No 9 (81.8) 197 (95.6)
Note: Missing observations: race,n = 1; vaginal bleeding, n = 1; cigarette smoking, n = 1; marijuana use, n = 1; crack/cocaine use, n = 61; prior incompetent
cervix, n = 2; prior ectopic pregnancy, n = 41; history of STD, n = 5; history of PID, n = 3; history of problems getting pregnant, n = 2.
(a)P-value not calculated.
(b)Gestational age at enrollment in weeks.
(c)t-test P-value =.78.
(d)Detected in hair sample collected at enrollment and/or self-reported cocaine use.
(e)C. trachomatis, N. gonorrhoeae, syphilis, genital warts, Trichomonas vaginalis, and/or BV.
Table 3: Odds of spontaneous abortion according to infection at enrollment.
Infection
Women who experienced a
SAB n = 82
Women who maintained their




Yes 3 (3.7) 9 (6.7) 0.5 (0.1–2.0) 0.9 (0.2–3.8)
No 79 (96.3) 125 (93.3)
(a)Adjusted for age, history of SAB, smoking, and gestational age.
with both bacteria. Participants were predominantly less
than 30 years old (82%), African-American (90%), not
married (81%), and receiving government assistance at time
of enrollment (59%). Nearly two-thirds of the women (62%)
reported a history of STDs. The mean gestational age at
enrollment was 9.2 weeks.
Compared to control women, cases were signiﬁcantly
more likely to report vaginal bleeding both within 24 hours
of the enrollment visit (57.3% versus 21.8%, P<. 0001)
and at any time during pregnancy (65.4% versus 37.3%,
P<. 0001)(Table 1).Caseswerealsosigniﬁcantlymorelikely
to report a previous SAB (40.2% versus 26.1%, P = .03) than
controls. These were the only characteristics that diﬀered
between cases and controls. Results remained the same after
excluding women with vaginal bleeding at baseline.
Compared to women who tested negative for M. genital-
ium,womenwhotestedpositiveforM.genitaliumwere more
likely to report nulliparity (41.7% versus 17.4%, P = .04),
a history of PID (27.3% versus 8.8%, P = .08), prior C.
trachomatis infection (63.6% versus 36.9%, P = .11), and
problems getting pregnant (18.2% versus 4.4%, P = .10)
(Table 2). Although results were not statistically signiﬁcant,
the direction of the association remained the same after
adjusting for C. trachomatis P C R( n u l l i p a r i t yA O R3 . 4 ,9 5 %
CI 1.0–11.6; history of PID AOR 3.9, 95% CI 0.9–16.1; prior
C.trachomatisinfectionAOR3.0,95%CI0.8–10.5;problems
getting pregnant AOR 4.8, 95% CI 0.9–25.7). After adjusting
for age, nulliparous women were still more likely to test
positive for M. genitalium than women who did not report
nulliparity, but the results were not statistically signiﬁcant
(AOR 2.8, 95% CI 0.8–9.8).
M. genitalium was not independently associated with
SAB, after adjusting for age, history of SAB, smoking during
pregnancy, and gestational age (AOR 0.9, 95% CI 0.2–
3.8) (Table 3). Results were similar after further adjusting
for self-reported BV (AOR 0.4, 95% CI 0.08–1.9) and
after excluding women who experienced vaginal bleeding at
enrollment (OR 0.4, 95% CI 0.1–3.8). When history of SAB
wasremovedfromthemultivariatemodel,M.genitaliumwas
not associated with SAB.6 Infectious Diseases in Obstetrics and Gynecology
Nearly 28% (22/79) of the cases experienced a SAB at
less than 11 weeks gestation. Among these cases, none tested
positive for M. genitalium. Among the cases that experienced
a SAB at 11 or greater weeks of gestation, 4.3% (2/46) tested
positive for M. genitalium. M. genitalium was not associated
with SAB (OR 0.6, 95% CI 0.1–3.0), even after adjusting
for age, history of SAB, smoking and gestational age at
enrollment (AOR 1.0, 95% CI 0.2–6.5)
4. Disscusion
To our knowledge, ours was the ﬁrst study to prospectively
evaluate the relationship between M. genitalium and subse-
quent SAB among a high-risk pregnant population and we
found that M. genitalium in pregnancy was not associated
with subsequent SAB. Our null ﬁndings are consistent with
those of two other studies of M. genitalium and SAB.
Oakeshott et al. used PCR to test urine samples from 915
pregnant women presenting at prenatal care at less than
10 weeks gestation in general practice and family planning
clinics in London [11]. Only 0.66% of the samples tested
positive for M. genitalium [11]. Women who experienced
a subsequent SAB were not more likely to test positive
for M. genitalium compared to the women who did not
experience a SAB (1% versus 0.6%, P = NS)[ 11]. Although
the rate of M. genitalium was higher among SAB cases in
this study, the power to detect a signiﬁcant diﬀerence was
likely limited, due to the small number of women testing
positive for M. genitalium (n = 6) [11]. In a case-control
study of 1014 recently pregnant women in Guinea-Bissau,
M. genitalium detected by PCR in cervical samples collected
within 24 hours of a SAB or delivery of a term neonate was
not associated with SAB (OR 0.61, 95% CI 0.07–2.5) [24].
In our study, although we had a modest sample size, M.
genitalium was more prevalent than reported in the study
by Oakeshott et al. (5.6% versus 0.66%), and we had a
power of 80% to detect approximately a threefold increased
risk of SAB among M. genitalium positive patients. Our
higher prevalence might be expected, as women in our
study population were probably at high risk for STDs in
general, as they were predominantly young, single, African-
American, of lower socioeconomic status (SES) and reported
a history of STDs. Further, in contrast to Labbe et al.,
who tested for M. genitalium at the time of SAB and
delivery, we tested for M. genitalium prior to pregnancy
loss. Therefore, unlike the previous studies of M. genitalium
and SAB, our prospectively designed study allowed us to
establishatemporalrelationshipbetweenearlypregnancyM.
genitalium and subsequent SAB among a high-risk pregnant
population.
In our study, the clinical, demographic, and behavioral
characteristics of pregnant women who tested positive for
M. genitalium and women who did not were similar. Our
results are similar to those reported by Labbe et al., in which
M. genitalium was not associated with any demographic,
behavioral, clinical, or laboratory characteristic, including
age, age at sexual debut, number of sexual partners, previous
pregnancies, syphilis, HIV serology, N. gonorrhoeae and T.
vaginalis (P>. 05 for all) [24]. Conversely, Oakeshott et al.
found that M. genitalium was more common in pregnant
women who were less than 20 years of age (P = .002), black
(P = .034), single (P = .017), and had lower SES (P = .007)
[11]. Our null ﬁndings were likely due to the fact that our
studypopulationwasafairlyhomogeneousgroupofwomen,
which may have biased our results toward the null.
Although M. genitalium was not associated with SAB or
demographic and behavioral characteristics, it was associ-
ated with a history of other gynecologic and reproductive
morbidities, including history of PID, prior chlamydial
infection and problems getting pregnant. Further, our results
suggest an independent relationship between M. genitalium
and these conditions, as the results remained the same
even after adjusting for the presence of C. trachomatis.
Our results are consistent with other studies that have
identiﬁed M. genitalium as a possible etiologic agent of
other adverse reproductive conditions, such as nongonococ-
cal/nonchlamydial PID [17–20] and PID-associated sequelae
[19], including tubal factor infertility [22, 23]. It may be
that M. genitalium was not associated with SAB in our study
population of pregnant women because women with M.
genitalium go on to develop PID and subfertility and would
therefore not be enrolled in our study. Results from this
study support the need for further research on the role of M.
genitalium in reproductive and adverse pregnancy outcomes.
While it is suggested that M. genitalium is associated with
impairedfertility,larger,prospectivestudiesamongpregnant
women and women trying to conceive are needed.
There are a few limitations to recognize as part of this
study. First, the small sample sizes of some of our subgroups
limited statistical power. Second, the mean gestational age
at enrollment was approximately 9 weeks, so earlier SABs
would have been missed. Still, the gestational age ranged
from 1 to 15, so early SAB was included. Furthermore, in
subgroup analyses stratiﬁed by gestational age at enrollment,
results were not diﬀerent. Third, the use of self-report as
a means of collecting information can introduce several
biases and may not be a very accurate measure. Although
gestational age was calculated on the basis of self-reported
date of the last menstrual period, which may over or
underestimate the true date, nearly 72% of participants had
their estimated due date conﬁrmed by pelvic ultrasound.
Finally,onlyarchivedmid-streamurine(MSU)sampleswere
available for M. genitalium testing in our EPS substudy,
and this may have limited our analyses. While there are
no data on the sensitivity of M. genitalium PCR in MSU
versus ﬁrst void urine (FVU) samples, C. trachomatis studies
have found that MSU had a sensitivity of 86% to 95%
compared to FVU [31]. Thus, we expect that MSU M.
genitalium PCR yielded results in our study which would
be similar to those using FVU, which Jensen et al. have
previously published as the most sensitive specimen type
for the detection of M. genitalium by PCR, as compared
to cervical and urethral swab specimens [30]. In a study
comparing the eﬃcacy of FVU with cervical and urethral
swab specimens for detection of M. genitalium using in-
house inhibitor-controlled PCR assays, more infections were
detected using urine samples (88%) than cervical (71%) and
urethral swab specimens (57%), and the urine specimen wasInfectious Diseases in Obstetrics and Gynecology 7
signiﬁcantly more eﬃcient than both the cervical (P = .049)
and the urethral swab specimen (P = .0009) [30]. However,
for optimal sensitivity, urine should be supplemented with a
cervical specimen. In our study, the addition of a cervical or
vaginal specimen for PCR may have increased the sensitivity
a n dd e t e c t e dm o r eM. genitalium positive women. However,
cervical samples were not available for testing. Therefore, the
reportedprevalenceofM.genitaliuminourstudypopulation
may be an underestimate of the true prevalence in our study
population. The null relationship between M. genitalium
urine PCR and SAB may further be explained by the fact
that some women did not have upper genital tract infection,
but instead had only urinary or lower genital tract infection,
insuﬃcient to cause SAB.
5. Conclusions
In conclusion, among this population of mostly young,
single, African-American pregnant women, M. genitalium
was not predictive of SAB. However, trends between M.
genitalium and a history of gynecologic and reproductive
morbidities, including other STDs, PID, and problems
getting pregnant were evident, even after adjusting for C.
trachomatis. Results from this study support the need for
further research on the role of M. genitalium in reproductive
and adverse pregnancy outcomes. While it is suggested that
M. genitalium is associated with impaired fertility, larger,
prospective studies among pregnant women and women
trying to conceive are needed. Such studies should consider
testing for M. genitalium in cervical or vaginal specimens
from women recruited prior to pregnancy or from women
early in gestation.
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